Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
←Back to story

Roche enters the SERD market with FDA approval in late-stage breast cancer

EndpointsView source article

Part of story

FDA approves Roche's giredestrant pill for advanced breast cancer

The FDA approved Roche's oral SERD giredestrant in combination with Novartis's everolimus for advanced or metastatic breast cancer, reducing risk of progression or death by 62%. This marks Roche's entry into the competitive SERD market.

Nov 17, 2026·3 sourcesClinical trialsPrecision medicineFDA drug approvalDrug Policy, Pricing & ApprovalCancer treatmentTargeted cancer therapyCancer and Cancer TreatmentOncologyCancer & Oncology
FDA approves Roche's giredestrant pill for advanced breast cancer
00

Other sources for this story

The Wall Street Journal

Roche Secures First U.S. Approval for New Breast-Cancer Pill

MedPage Today

Next-Generation Oral SERD Approved for Breast Cancer